Poster-Disease-modifying Therapy
October 25, 2021
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies
Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...
Poster-Disease-modifying Therapy
October 25, 2021
Multiple Sclerosis Disease Modifying Therapies Adherence and Total Medical Costs Among Women with Maternity Services Using Administrative Data.
Background: Women with multiple sclerosis (MS) who become pregnant and utilize maternity services may find their use of disease-modifying...
Poster-Disease-modifying Therapy
October 25, 2021
Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study
Background: In relapsing forms of Multiple Sclerosis, disability progression has been shown to be independent of relapses. A new concept in...
Poster-Disease-modifying Therapy
October 25, 2021
Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)
Background: In 2018, the MS world received its first true generic DMT, and more generics will become available over the next few years....
Poster-Disease-modifying Therapy
October 25, 2021
MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity
Background: NEDA or No evidence of disease activity (relapses, MRI lesions and disease progression) is increasingly used as a meaningful...
Poster-Disease-modifying Therapy
October 25, 2021
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...
Poster-Disease-modifying Therapy
October 25, 2021
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...